TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03662867

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-based mindfulness intervention
Description: For the parent program of family-based mindfulness intervention, the content includes: guide body scan practice; guide stretching exercise and mindful breathing; guide practice of mindfulness to breath and body; teach three-minute breathing exercise; guide joint session and let parents practice mindfulness with children; guide mindfulness practice of exploring difficulties; and teach loving-kindness practice.~For the child program, the content includes: guide mindful breathing exercise; guide mindful movement exercises; use stories of animal characters to guide body scan exercise; guide mindful eating and mindful walking exercise; tell stories about different emotions and guide discussion; guide the imagination exercise about different emotions; and guide loving-kindness practice.

Intervention type: OTHER
Group type: OTHER
Intervention: Wait-list
Description: No intervention is given between T1 and T2. Family-based mindfulness intervention would be received after posttest of intervention groups.
Study: NCT00657319

Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: The observation is performed under normal clinical practice conditions without any additionally required diagnostic/therapeutic features. Physicians are allowed to decide the treatment regimen according to the medical standards.
Study: NCT03866746

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aflibercept Injection
Description: Group A;Under complete aseptic conditions; intravitreal aflibercept injections with dose of 2 mg/0.05 mL per injection was given for the patients. Patients were scheduled to receive 3 loading injections at monthly interval. At the 3rd month; further treatment was planned pro re nata (PRN) according to the response. Injections were discontinued when the CMT reached 250 µm or less. If there was no change in the CMT after two consecutive injections; patients shifted to other line of treatment. Reinjection was continued for the other eyes with re-evaluation of the response every month.In group B Patients received the initial 3 monthly loading doses of IVI of aflibercept followed by MPL therapy (within one week after the 3rd injection). Patients were scheduled for follow-up monthly. Injection followed by MPL was then repeated according to the response as in group A.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept Injection
Description: Group A;Under complete aseptic conditions; intravitreal aflibercept injections with dose of 2 mg/0.05 mL per injection was given for the patients. Patients were scheduled to receive 3 loading injections at monthly interval. At the 3rd month; further treatment was planned pro re nata (PRN) according to the response. Injections were discontinued when the CMT reached 250 µm or less. If there was no change in the CMT after two consecutive injections; patients shifted to other line of treatment. Reinjection was continued for the other eyes with re-evaluation of the response every month.In group B Patients received the initial 3 monthly loading doses of IVI of aflibercept followed by MPL therapy (within one week after the 3rd injection). Patients were scheduled for follow-up monthly. Injection followed by MPL was then repeated according to the response as in group A.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: micropulsed yellow laser
Description: Micropulse yellow IQ 577nm laser (Iridex Corporation, Mountain View, CA, USA) was employed. The Area Centralis lens (laser spot size magnification 0.94) was utilized with 400 mw power, 200μm spot size and 200 ms pulse duration with 5% duty cycle after micropulse mode activation. Laser was applied on clinically visible thickened macula with different number of confluent non- spacing shots in 7x7 grids. Care was taken to begin treatment outside the foveal avascular zone and not to treat the fovea when there was no visible reaction. If there was any visible reaction; treatment was stopped and the power was reduced until there was no visible reaction.
Study: NCT02758210

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of a Tablet
Description: Testing of the electromagnetic field exposure and it's affect on the participant's previously implanted MICRA device is assessed by interrogation of the device before using Tablet and while using the Tablet. The measured position of the Tablets tested will be normal routine position (noting at least 6 inches/15 centimeters from their pacemaker).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Use of a Smart Phone
Description: Testing of the electromagnetic field exposure and it's affect on the participant's previously implanted MICRA device is assessed by interrogation of the device before using a Smart phone and while using the Smart phone. The position of the Smart phone tested will be normal position at the ear and while texting (noting at least 6 inches/15 centimeters from their pacemaker).
Study: NCT03541122

Intervention type: DIAGNOSTIC_TEST
Intervention: pelvic X-ray examinations
Description: Measurement indicators will include OFI, MUI, TBOI, CE angle, Sharp angle and AHI of the affected and healthy femoral heads.
Study: NCT02249364

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Routine practice

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: Hypnosis session before induction of anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Description: Closed-loop administration of propofol for anesthesia induction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propofol
Description: Closed-loop administration of propofol for anesthesia induction
Study: NCT01007201

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A (H1N1) 2009 monovalent vaccine, inactivated

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza A (H1N1) 2009 monovalent vaccine, inactivated
Study: NCT03293108

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: Denosumab 60 mg is subcutaneously administered to osteoporotic patients at baseline, month 6 and month 12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: Denosumab 60 mg is subcutaneously administered to osteoporotic patients at baseline, month 6 and month 12.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: calcium
Description: All women will receive daily supplements containing at least 1000 mg of elemental calcium (divided in two doses), during 18 month of the study.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcium
Description: All women will receive daily supplements containing at least 1000 mg of elemental calcium (divided in two doses), during 18 month of the study.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D
Description: All women will receive daily supplements containing at least 400 IU vitamin D daily during 18 month of the study.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: All women will receive daily supplements containing at least 400 IU vitamin D daily during 18 month of the study.
Study: NCT03524430

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Core needle biopsy
Description: 1st core needle biopsy for RDA (2 specimens): Time Point: 35 +/-4 days after initiation of chemotherapy.~If no change is made to the therapy, a second biopsy (2 specimens) will be performed at 55 +/- 5 days after therapy initiation.~If there is a change of drugs, the second biopsy (2 specimens) will be performed at \~2-3 weeks after initiation of new drugs; Timing by type of drug schedule 3-weekly: at 16 days +/- 2 days, Bi-weekly: at day of 2nd dose preferably before drug admin., Weekly: at day of 4th dose preferably before drug admin.
Study: NCT02973971

Intervention type: OTHER
Intervention: volumeric MRI

Intervention type: OTHER
Intervention: volumeric MRI
Study: NCT02616991

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography venography
Description: systematically performing computed tomography venography in addition to thoracic computed tomography angiography
Study: NCT01917058

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: This will be a randomized double blind placebo controlled study. Patients will be randomly assigned to abatacept or placebo in a 1:1 ratio based on a computer generated randomization list. The list will be generated prior to study initiation. Based on the randomization list, patients will be assigned to treatment vs. vehicle (provided by BMS) in the order in which they are enrolled. The assignment will be made by study personnel who are not involved in making clinical assessments or evaluations. The patient and the assessing physicians will remain blinded to the treatment assignment for the duration of the study.~Patients will be treated with abatacept 125mg SC self-administered each week. Treatment will be continued for 6 months to provide adequate time to assess the short-term efficacy and safety of abatacept in patients with alopecia areata. Patients will then be followed for an additional 6 months to assess the timing and incidence of relapse.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00949182

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate, HACE : Doxorubicin Hydrochloride and Mitomycin C
Description: After Sorafenib Tosylate has been administered the actual HACE procedure is performed using Doxorubicin Hydrochloride or Mitomycin C

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study: NCT03341299

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LY900014
Description: Administered SC

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro
Description: Administered SC
Study: NCT03466385

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal High Flow
Description: Patients admitted to emergency department with COPD exacerbation combined with mild to moderate acute or acute on chronic hypercapnic respiratory failure will be randomized in one of the two study groups. In case of NHF it will be commence immediately with pre-defined settings

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-Invasive Ventilation
Description: Patients admitted to emergency department with COPD exacerbation combined with mild to moderate acute or acute on chronic hypercapnic respiratory failure will be randomized in one of the two study groups. In case of NIV it will be commence immediately with pre-defined settings
Study: NCT03725670

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lentivirus-mediated delivery of ARSA to the CNS.
Description: Intracerebral LV gene therapy to deliver high level lenviral vectors which carry normal ARSA gene at 1-2×10\^9 multiplicity of infection (moi)/ml per site.
Study: NCT03685760

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Reiki therapy
Description: Reiki, a complementary health approach where trained practitioners place their hands lightly on or just above a person, in discrete positions, with the goal of facilitating the person's own healing response. Reiki therapists will administer the Reiki intervention (i.e., a 30-minute treatment in which the subject is lightly touched for 3 minutes at each of 10 standardized Reiki hand positions).

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Reiki
Description: Sham (pretend) Reiki therapists will administer the sham Reiki intervention (i.e., a 30-minute treatment in which the subject is lightly touched for 3 minutes at each of 10 standardized Reiki hand positions). Sham providers do not have Reiki training.
Study: NCT05720286

Intervention type: DEVICE
Intervention: Arthroscopic rotator cuff repair
Description: Arthroscopic transosseous reinsertion of the rotator cuff is the most widely used arthroscopic technique. The tendons are repositioned on the greater and lesser tuberosities of the humerus with specific anchors. These anchors, placed in the humeral bone, are attached to sutures which are in turn tied to the tendon.
Study: NCT01526447

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Craniosacral Therapy
Description: Standardized therapy protocol (according to Upledger): Still point technique, diaphragm release, compression-decompression and lift techniques of the cranial bones, facial balancing in the region of shoulder and pelvis and somato-emotional unwinding

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Craniosacral Therapy
Description: Standardized sham protocol: Placing hands on various parts of the clothed body for two minutes each time without therapeutic intention
Study: NCT03363373

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GM-CSF + Naxitamab
Description: Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and Humanized IgG1 monoclonal GD2 antibody
Study: NCT03676842

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: FLEX Dynamic Scoring Catheter with IN.PACT Admiral DCB
Description: Treatment by the FLEX Scoring Catheter followed by an IN.PACT Admiral DCB
Study: NCT02981108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10296
Description: HS-10296: 5-, 10-, 40-, and 55-mg tablet, immediate-release formulation. Patients should avoid consumption of food for at least 1 hour prior to and 2 hours post dosing. RP2D is determined at 110 mg QD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10296
Description: HS-10296: 5-, 10-, 40-, and 55-mg tablet, immediate-release formulation. Patients should avoid consumption of food for at least 1 hour prior to and 2 hours post dosing. RP2D is determined at 110 mg QD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10296
Description: HS-10296: 5-, 10-, 40-, and 55-mg tablet, immediate-release formulation. Patients should avoid consumption of food for at least 1 hour prior to and 2 hours post dosing. RP2D is determined at 110 mg QD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10296
Description: HS-10296: 5-, 10-, 40-, and 55-mg tablet, immediate-release formulation. Patients should avoid consumption of food for at least 1 hour prior to and 2 hours post dosing. RP2D is determined at 110 mg QD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10296
Description: HS-10296: 5-, 10-, 40-, and 55-mg tablet, immediate-release formulation. Patients should avoid consumption of food for at least 1 hour prior to and 2 hours post dosing. RP2D is determined at 110 mg QD.
Study: NCT03482726

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cycling Cadence Modulation
Description: 6-week high intensity training (HIIT) indoor cycling program, described later, at their prescribed cadence (FCC or EOC), using cadence meters.
Study: NCT02744092

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: Anticoagulation therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban
Description: Anticoagulation therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: Anticoagulation therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: Anticoagulation therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Edoxaban
Description: Anticoagulation therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Edoxaban
Description: Anticoagulation therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran
Description: Anticoagulation therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran
Description: Anticoagulation therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Anticoagulation therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Anticoagulation therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalteparin
Description: Anticoagulation therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dalteparin
Description: Anticoagulation therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Anticoagulation therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Anticoagulation therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fondaparinux
Description: Anticoagulation therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fondaparinux
Description: Anticoagulation therapy.
Study: NCT01151488

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: RT 3x/wk for 4 months
Study: NCT02923141

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Neutral Writing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Expressive Writing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency Management

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contingency Management
Study: NCT02855008

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEPS
Description: Agencies providing residential services to individuals with ID gave us letters of agreement (N=9) when we submitted for funding. We randomized these agencies and followed the specific order. Over the past year, recruitment issues have resulted in our only being able to recruit at six of the original nine agencies. To address the issues, we compiled a list of 15 additional local agencies within a 50 mile radius. We are recruiting from an additional six agencies and are in contact with another four. We also changed our recruitment criteria to include co-ed homes. Within each agency we then, (1) determine homes that that meet criteria and, by gender (male, female, co-ed), randomize to STEPS or attention-control condition. Residential staff are consented first. Individuals with ID (or guardians if they have one) are then consented. 18 homes will participate in STEPS.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Food for Life
Description: Agencies providing residential services to individuals with ID gave us letters of agreement (N=9) when we submitted for funding. We randomized these agencies and followed the specific order. Over the past year, recruitment issues have resulted in our only being able to recruit at six of the original nine agencies. To address the issues, we compiled a list of 15 additional local agencies within a 50 mile radius We are recruiting from an additional six agencies and are in contact with another four. We also changed our recruitment criteria to include co-ed homes. Within each agency we then, (1) determine homes that that meet criteria and, by gender (male, female, co-ed), randomize to STEPS or attention-control condition. Individuals with ID and staff are recruited after randomization. Residential staff are consented first. Individuals with ID (or guardians if they have one) are then consented. 18 homes will participate in Food for Life.
Study: NCT01673308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 10 mg orally on days 1 to 21 of a 28-day cycle for at least 4 cycles until intolerance or disease progression.
Study: NCT03238716

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electric DN
Description: Dry needling with electric stimulation to the erector spine and paraspinal muscles in the lumbar / sacral region and tibialis anterior / posterior. Dry needling with electric stimulation of peri-neural tissue associated with lumbar / sacral nerve roots, pudendal nerve and posterior tibial nerve. 8-12 treatment sessions over 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NM Re-ed
Description: sEMG targeting type I slow-twitch fibers and type II fast-twitch fibers. Type I fibers maintain continuous muscle activity over prolonged periods of time; therefore, training of type I fibers will be achieved through endurance and repetition training of the pelvic floor muscles. Type II fibers are recruited during sudden increases in intra-abdominal pressure, and these fibers will be recruited with The Knack training. The Knack is a term created to use rhythm or timing to the pelvic floor. Neuromuscular re-education will be performed during the first treatment, but it will be performed as needed on subsequent treatments.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: NM Re-ed
Description: sEMG targeting type I slow-twitch fibers and type II fast-twitch fibers. Type I fibers maintain continuous muscle activity over prolonged periods of time; therefore, training of type I fibers will be achieved through endurance and repetition training of the pelvic floor muscles. Type II fibers are recruited during sudden increases in intra-abdominal pressure, and these fibers will be recruited with The Knack training. The Knack is a term created to use rhythm or timing to the pelvic floor. Neuromuscular re-education will be performed during the first treatment, but it will be performed as needed on subsequent treatments.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Impairment-specific strength training, which may include transversus abdominis (TrA), gluteus maximus/medius/minimus and/or hip abductor/adductor muscle training. Treadmill, riding the recumbent bike at \> 2 METs and/or stair climbing. Exercise training will be performed 7-11 treatment sessions over 6 weeks (following treatment 1).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Impairment-specific strength training, which may include transversus abdominis (TrA), gluteus maximus/medius/minimus and/or hip abductor/adductor muscle training. Treadmill, riding the recumbent bike at \> 2 METs and/or stair climbing. Exercise training will be performed 7-11 treatment sessions over 6 weeks (following treatment 1).